Examples of using Zelboraf in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
If you stop taking Zelboraf.
Zelboraf is not recommended for use in melanoma patients with wild-type BRAF.
If you forget to take Zelboraf.
Zelboraf is not recommended for use in melanoma patients who lack the BRAF V600E mutation.
Talk to your doctor before taking Zelboraf.
Our skin cancer drug, Zelboraf, and its companion test were both approved in the US in 2011 in record time.
You should have your eyes examined by your doctor while you are taking Zelboraf.
Zelboraf is used to treat adults with melanoma(a type of skin cancer) that has spread to other parts of the body or cannot be surgically removed.
Phase III coBRIM study demonstrated a medianprogression-free survival of 12.3 months with cobimetinib plus Zelboraf.
Zelboraf is not recommended for use during pregnancy unless your doctor considers that the benefit for the mother outweighs the risk for the baby.
Your doctor will also do some blood tests to check your liver and kidney functions before you start taking Zelboraf and during treatment.
Zelboraf and Erivedge, therapies for two of the most difficult-to-treat skin cancers, metastatic melanoma and basal cell carcinoma, have been used to treat more than 28,000 patients worldwide.
Roche announced today that the European Commission has approved CotellicTM(cobimetinib)for use in combination with Zelboraf(vemurafenib) for the treatment of adult patients with unresectable or….
Zelboraf was the first prescription treatment for patients with unresectable or metastatic melanoma with BRAF V600 mutation as detected by a validated test, such as Roche's cobas 4800 BRAF Mutation Test.
Roche today announced data from the pivotal coBRIM study, which showed that Cotellic(cobimetinib)in combination with Zelboraf(vemurafenib) helped people with BRAF V600E and V600K mutation-positive….
Cotellic and Zelboraf are prescription medicines used in combination to treat melanoma that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal"BRAF" gene.
Roche, today announced that the Committee for Medicinal Products for Human Use(CHMP)has recommended that Zelboraf be granted full marketing authorization as a monotherapy for the treatment of adult….
Erivedge(basal cell carcinoma) was approved in the US, Zelboraf(metastatic melanoma) received marketing approval in the EU, and the US Food and Drug Administration(FDA) has granted pertuzumab priority review for HER2-positive breast cancer.
Perjeta for HER2-positive metastatic breast cancer andErivedge for advanced basal cell carcinoma in the United States, and Zelboraf for BRAF V600 mutation-positive metastatic melanoma in Europe.
Today, treatments such as Zelboraf(vemurafenib) are helping to stall the growth or spread of the cancer and are enabling patients to survive longer, for the first time extending life expectancy beyond one year for many patients.
Additional data were presented on November 21, 2015 at the Society for Melanoma Research congress demonstrating that the combination of Cotellic plus Zelboraf met its secondary endpoint of improving overall survival compared to Zelboraf alone.
Zelboraf has also recently been approved in Switzerland, Brazil, Israel, Canada and New Zealand and marketing authorization submissions are currently under review by health authorities in Australia, India and other countries worldwide.
More than 28,000 patients having been treated worldwide,bringing about medical breakthroughs and new standards of care that include Zelboraf and Erivedge, treatments for two of the most difficult-to-treat skin cancers, metastatic melanoma and basal cell carcinoma.
The test has several advantages over the widely used Sanger sequencing method, including greater sensitivity and reliability in detecting mutations and faster results indicating whether a person withmetastatic melanoma is eligible for treatment with Zelboraf.
BRIM3 is a global, randomized, open-label, controlled, multicenter,Phase III study that compared Zelboraf to dacarbazine chemotherapy, a standard of care, in 675 patients with previously untreated BRAF V600E mutation-positive, unresectable(inoperable) or metastatic melanoma.
CoBRIM is an international, randomised, double-blind, placebo-controlled Phase III study evaluating the safety and efficacy of 60 mg once daily of Cotellic plus 960 mg twice daily of Zelboraf compared to 960 mg twice daily of Zelboraf alone.
The test has several advantages over Sanger sequencing, a commonly used method, including greater sensitivity and reliability in detecting mutations and faster results, allowing doctors to know whether a person withmetastatic melanoma is eligible for treatment with Zelboraf.
The company announced final phase III data showing a significant increase in overall survival, and in September, the Committee for Medicinal Products for Human Use(CHMP)recommended EU approval for Cotellic plus Zelboraf for the treatment of patients with BRAF V600 mutation-positive metastatic melanoma.
CoBRIM is an international, randomised, double-blind, placebo-controlled Phase III study evaluating the safety and efficacy of 60 mg once daily of cobimetinib in combination with 960 mg twice daily of Zelboraf, compared to 960 mg twice daily of Zelboraf alone.